25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Rosetta Genomics Ltd
Buy, Hold or Sell?

Let's analyze Rosetta Genomics Ltd together

I guess you are interested in Rosetta Genomics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Rosetta Genomics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Rosetta Genomics Ltd

I send you an email if I find something interesting about Rosetta Genomics Ltd.

1. Quick Overview

1.1. Quick analysis of Rosetta Genomics Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Rosetta Genomics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.74
Expected worth in 1 year
$-9.51
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-10.26
Return On Investment
-10,255,216.8%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.0001
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Rosetta Genomics Ltd (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-16.11 - $-18.61
Total Value Per Share
$-15.37 - $-17.87

2.2. Growth of Rosetta Genomics Ltd (5 min.)




Is Rosetta Genomics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$4.4m$19.6m-$15.2m-344.2%

How much money is Rosetta Genomics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$16.2m-$17.3m$1.1m6.9%
Net Profit Margin-175.8%-603.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Rosetta Genomics Ltd (5 min.)




2.4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Rosetta Genomics Ltd?

Welcome investor! Rosetta Genomics Ltd's management wants to use your money to grow the business. In return you get a share of Rosetta Genomics Ltd.

First you should know what it really means to hold a share of Rosetta Genomics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Rosetta Genomics Ltd is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rosetta Genomics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rosetta Genomics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.74. Based on the TTM, the Book Value Change Per Share is $-2.56 per quarter. Based on the YOY, the Book Value Change Per Share is $0.77 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rosetta Genomics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.74-2,737,501.4%-2.74-2,737,501.4%-2.93-2,925,026.9%-2.06-2,057,417.9%-1.03-1,028,708.9%
Usd Book Value Change Per Share-2.56-2,563,804.2%-2.56-2,563,804.2%0.77768,146.3%0.16160,981.9%-0.11-112,683.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.56-2,563,804.2%-2.56-2,563,804.2%0.77768,146.3%0.16160,981.9%-0.11-112,683.9%
Usd Price Per Share0.42-0.42-1.23-2.29-2.07-
Price to Earnings Ratio-0.15--0.15--0.42--0.57--0.28-
Price-to-Total Gains Ratio-0.16--0.16-1.60--0.33-0.19-
Price to Book Ratio0.56-0.56-0.37-0.69--0.52-
Price-to-Total Gains Ratio-0.16--0.16-1.60--0.33-0.19-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.560.16
Usd Total Gains Per Share-2.560.16
Gains per Quarter (10000000 shares)-25,638,042.041,609,818.78
Gains per Year (10000000 shares)-102,552,168.186,439,275.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-102552168-102552178064392756439265
20-205104336-20510434601287855012878540
30-307656505-30765651401931782519317815
40-410208673-41020868202575710125757090
50-512760841-51276085003219637632196365
60-615313009-61531301803863565138635640
70-717865177-71786518604507492645074915
80-820417345-82041735405151420151514190
90-922969514-92296952205795347657953465
100-1025521682-102552169006439275164392740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.04.01.00.0%0.04.06.00.0%0.04.09.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%6.07.00.046.2%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.013.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%6.07.00.046.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Rosetta Genomics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.564-2.5640%0.768-434%0.161-1693%-0.113-96%
Book Value Per Share--0.7450.7450%3.309-77%3.158-76%2.347-68%
Current Ratio--2.5012.5010%6.910-64%5.950-58%2.975-16%
Debt To Asset Ratio--0.6310.6310%0.125+405%0.204+209%0.407+55%
Debt To Equity Ratio--1.7081.7080%0.143+1096%0.429+298%0.458+273%
Dividend Per Share----0%-0%-0%-0%
Eps---2.738-2.7380%-2.925+7%-2.057-25%-1.029-62%
Free Cash Flow Per Share---1.805-1.8050%-2.875+59%-2.228+23%-2.228+23%
Free Cash Flow To Equity Per Share---1.255-1.2550%0.046-2857%-0.949-24%-0.949-24%
Gross Profit Margin--1.0001.0000%1.0000%0.800+25%0.400+150%
Intrinsic Value_10Y_max---18.613--------
Intrinsic Value_10Y_min---16.111--------
Intrinsic Value_1Y_max---2.242--------
Intrinsic Value_1Y_min---2.178--------
Intrinsic Value_3Y_max---6.448--------
Intrinsic Value_3Y_min---6.095--------
Intrinsic Value_5Y_max---10.309--------
Intrinsic Value_5Y_min---9.489--------
Market Cap592.986-419900%2490541.2002490541.2000%7293727.800-66%13591239.120-82%12245220.199-80%
Net Profit Margin---1.758-1.7580%-6.033+243%-10.116+475%-5.058+188%
Operating Margin---1.368-1.3680%-4.556+233%-9.924+625%-4.962+263%
Operating Ratio--3.5023.5020%5.905-41%19.721-82%27.868-87%
Pb Ratio0.000-419900%0.5640.5640%0.372+52%0.689-18%-0.516+191%
Pe Ratio0.000+100%-0.153-0.1530%-0.421+174%-0.568+270%-0.284+85%
Price Per Share0.000-419900%0.4200.4200%1.230-66%2.292-82%2.065-80%
Price To Free Cash Flow Ratio0.000+100%-0.233-0.2330%-0.428+84%-0.634+172%-0.317+36%
Price To Total Gains Ratio0.000+100%-0.164-0.1640%1.601-110%-0.326+99%0.190-186%
Quick Ratio--0.1350.1350%0.934-86%1.810-93%1.726-92%
Return On Assets---1.357-1.3570%-0.774-43%-0.694-49%-0.347-74%
Return On Equity---3.675-3.6750%-0.884-76%-1.214-67%-0.607-83%
Total Gains Per Share---2.564-2.5640%0.768-434%0.161-1693%-0.113-96%
Usd Book Value--4417000.0004417000.0000%19620000.000-77%18727000.000-76%13919600.000-68%
Usd Book Value Change Per Share---2.564-2.5640%0.768-434%0.161-1693%-0.113-96%
Usd Book Value Per Share--0.7450.7450%3.309-77%3.158-76%2.347-68%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---2.738-2.7380%-2.925+7%-2.057-25%-1.029-62%
Usd Free Cash Flow---10704000.000-10704000.0000%-17050000.000+59%-10567400.000-1%-5283700.000-51%
Usd Free Cash Flow Per Share---1.805-1.8050%-2.875+59%-2.228+23%-2.228+23%
Usd Free Cash Flow To Equity Per Share---1.255-1.2550%0.046-2857%-0.949-24%-0.949-24%
Usd Market Cap592.986-419900%2490541.2002490541.2000%7293727.800-66%13591239.120-82%12245220.199-80%
Usd Price Per Share0.000-419900%0.4200.4200%1.230-66%2.292-82%2.065-80%
Usd Profit---16233000.000-16233000.0000%-17345000.000+7%-12200200.000-25%-6100100.000-62%
Usd Revenue--9234000.0009234000.0000%2875000.000+221%2808400.000+229%1608500.000+474%
Usd Total Gains Per Share---2.564-2.5640%0.768-434%0.161-1693%-0.113-96%
 EOD+3 -5MRQTTM+0 -0YOY+11 -225Y+10 -2410Y+8 -26

3.3 Fundamental Score

Let's check the fundamental score of Rosetta Genomics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than0-1.758
Operating Margin (MRQ)Greater than0-1.368
Quick Ratio (MRQ)Greater than10.135
Current Ratio (MRQ)Greater than12.501
Debt to Asset Ratio (MRQ)Less than10.631
Debt to Equity Ratio (MRQ)Less than11.708
Return on Equity (MRQ)Greater than0.15-3.675
Return on Assets (MRQ)Greater than0.05-1.357
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Rosetta Genomics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Rosetta Genomics Ltd

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

Fundamental data was last updated by Penke on 2024-11-27 22:06:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Rosetta Genomics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Rosetta Genomics Ltd to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -175.8% means that $-1.76 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Rosetta Genomics Ltd:

  • The MRQ is -175.8%. The company is making a huge loss. -2
  • The TTM is -175.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-175.8%TTM-175.8%0.0%
TTM-175.8%YOY-603.3%+427.5%
TTM-175.8%5Y-1,011.6%+835.8%
5Y-1,011.6%10Y-505.8%-505.8%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-175.8%-5.6%-170.2%
TTM-175.8%-8.8%-167.0%
YOY-603.3%-0.8%-602.5%
5Y-1,011.6%-1.9%-1,009.7%
10Y-505.8%-0.5%-505.3%
4.3.1.2. Return on Assets

Shows how efficient Rosetta Genomics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rosetta Genomics Ltd to the Diagnostics & Research industry mean.
  • -135.7% Return on Assets means that Rosetta Genomics Ltd generated $-1.36 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Rosetta Genomics Ltd:

  • The MRQ is -135.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -135.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-135.7%TTM-135.7%0.0%
TTM-135.7%YOY-77.4%-58.4%
TTM-135.7%5Y-69.4%-66.3%
5Y-69.4%10Y-34.7%-34.7%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-135.7%-1.2%-134.5%
TTM-135.7%-2.1%-133.6%
YOY-77.4%-0.9%-76.5%
5Y-69.4%-0.1%-69.3%
10Y-34.7%-0.5%-34.2%
4.3.1.3. Return on Equity

Shows how efficient Rosetta Genomics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rosetta Genomics Ltd to the Diagnostics & Research industry mean.
  • -367.5% Return on Equity means Rosetta Genomics Ltd generated $-3.68 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Rosetta Genomics Ltd:

  • The MRQ is -367.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -367.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-367.5%TTM-367.5%0.0%
TTM-367.5%YOY-88.4%-279.1%
TTM-367.5%5Y-121.4%-246.1%
5Y-121.4%10Y-60.7%-60.7%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-367.5%-0.5%-367.0%
TTM-367.5%-1.7%-365.8%
YOY-88.4%0.3%-88.7%
5Y-121.4%-0.9%-120.5%
10Y-60.7%-0.9%-59.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Rosetta Genomics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Rosetta Genomics Ltd is operating .

  • Measures how much profit Rosetta Genomics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rosetta Genomics Ltd to the Diagnostics & Research industry mean.
  • An Operating Margin of -136.8% means the company generated $-1.37  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Rosetta Genomics Ltd:

  • The MRQ is -136.8%. The company is operating very inefficient. -2
  • The TTM is -136.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-136.8%TTM-136.8%0.0%
TTM-136.8%YOY-455.6%+318.8%
TTM-136.8%5Y-992.4%+855.6%
5Y-992.4%10Y-496.2%-496.2%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-136.8%-9.7%-127.1%
TTM-136.8%-12.8%-124.0%
YOY-455.6%3.3%-458.9%
5Y-992.4%0.5%-992.9%
10Y-496.2%3.1%-499.3%
4.3.2.2. Operating Ratio

Measures how efficient Rosetta Genomics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 3.50 means that the operating costs are $3.50 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Rosetta Genomics Ltd:

  • The MRQ is 3.502. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.502. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.502TTM3.5020.000
TTM3.502YOY5.905-2.403
TTM3.5025Y19.721-16.219
5Y19.72110Y27.868-8.146
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5021.254+2.248
TTM3.5021.284+2.218
YOY5.9051.266+4.639
5Y19.7211.208+18.513
10Y27.8681.191+26.677
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Rosetta Genomics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Rosetta Genomics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 2.50 means the company has $2.50 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Rosetta Genomics Ltd:

  • The MRQ is 2.501. The company is able to pay all its short-term debts. +1
  • The TTM is 2.501. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.501TTM2.5010.000
TTM2.501YOY6.910-4.410
TTM2.5015Y5.950-3.449
5Y5.95010Y2.975+2.975
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5012.028+0.473
TTM2.5012.113+0.388
YOY6.9102.555+4.355
5Y5.9502.668+3.282
10Y2.9753.229-0.254
4.4.3.2. Quick Ratio

Measures if Rosetta Genomics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rosetta Genomics Ltd to the Diagnostics & Research industry mean.
  • A Quick Ratio of 0.14 means the company can pay off $0.14 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Rosetta Genomics Ltd:

  • The MRQ is 0.135. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.135. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.135TTM0.1350.000
TTM0.135YOY0.934-0.799
TTM0.1355Y1.810-1.674
5Y1.81010Y1.726+0.084
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1351.228-1.093
TTM0.1351.241-1.106
YOY0.9341.803-0.869
5Y1.8102.100-0.290
10Y1.7262.435-0.709
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Rosetta Genomics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Rosetta Genomics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rosetta Genomics Ltd to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.63 means that Rosetta Genomics Ltd assets are financed with 63.1% credit (debt) and the remaining percentage (100% - 63.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Rosetta Genomics Ltd:

  • The MRQ is 0.631. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.631. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.631TTM0.6310.000
TTM0.631YOY0.125+0.506
TTM0.6315Y0.204+0.427
5Y0.20410Y0.407-0.203
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6310.437+0.194
TTM0.6310.440+0.191
YOY0.1250.359-0.234
5Y0.2040.428-0.224
10Y0.4070.450-0.043
4.5.4.2. Debt to Equity Ratio

Measures if Rosetta Genomics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rosetta Genomics Ltd to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 170.8% means that company has $1.71 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Rosetta Genomics Ltd:

  • The MRQ is 1.708. The company is just able to pay all its debts with equity.
  • The TTM is 1.708. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.708TTM1.7080.000
TTM1.708YOY0.143+1.565
TTM1.7085Y0.429+1.279
5Y0.42910Y0.458-0.029
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7080.640+1.068
TTM1.7080.686+1.022
YOY0.1430.502-0.359
5Y0.4290.666-0.237
10Y0.4580.712-0.254
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Rosetta Genomics Ltd generates.

  • Above 15 is considered overpriced but always compare Rosetta Genomics Ltd to the Diagnostics & Research industry mean.
  • A PE ratio of -0.15 means the investor is paying $-0.15 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Rosetta Genomics Ltd:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.153. Based on the earnings, the company is expensive. -2
  • The TTM is -0.153. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.153+0.153
MRQ-0.153TTM-0.1530.000
TTM-0.153YOY-0.421+0.267
TTM-0.1535Y-0.568+0.414
5Y-0.56810Y-0.284-0.284
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-0.407+0.407
MRQ-0.153-0.693+0.540
TTM-0.153-0.881+0.728
YOY-0.421-0.145-0.276
5Y-0.5681.937-2.505
10Y-0.2843.729-4.013
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Rosetta Genomics Ltd:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.233. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.233. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.233+0.233
MRQ-0.233TTM-0.2330.000
TTM-0.233YOY-0.428+0.195
TTM-0.2335Y-0.634+0.401
5Y-0.63410Y-0.317-0.317
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-0.595+0.595
MRQ-0.233-1.060+0.827
TTM-0.233-1.123+0.890
YOY-0.428-2.356+1.928
5Y-0.634-2.367+1.733
10Y-0.317-2.248+1.931
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Rosetta Genomics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 0.56 means the investor is paying $0.56 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Rosetta Genomics Ltd:

  • The EOD is 0.000. Based on the equity, the company is cheap. +2
  • The MRQ is 0.564. Based on the equity, the company is cheap. +2
  • The TTM is 0.564. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.000MRQ0.564-0.564
MRQ0.564TTM0.5640.000
TTM0.564YOY0.372+0.192
TTM0.5645Y0.689-0.125
5Y0.68910Y-0.516+1.205
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD0.0002.297-2.297
MRQ0.5642.330-1.766
TTM0.5642.320-1.756
YOY0.3722.384-2.012
5Y0.6893.753-3.064
10Y-0.5164.539-5.055
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2016-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets11,961
Total Liabilities7,544
Total Stockholder Equity4,417
 As reported
Total Liabilities 7,544
Total Stockholder Equity+ 4,417
Total Assets = 11,961

Assets

Total Assets11,961
Total Current Assets9,513
Long-term Assets2,448
Total Current Assets
Cash And Cash Equivalents 6,163
Short-term Investments 130
Net Receivables 385
Other Current Assets 4,371
Total Current Assets  (as reported)9,513
Total Current Assets  (calculated)11,049
+/- 1,536
Long-term Assets
Property Plant Equipment 625
Long Term Investments 6
Other Assets 1,817
Long-term Assets  (as reported)2,448
Long-term Assets  (calculated)2,448
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,804
Long-term Liabilities3,740
Total Stockholder Equity4,417
Total Current Liabilities
Short-term Debt 3,795
Short Long Term Debt 3,795
Accounts payable 872
Other Current Liabilities 874
Total Current Liabilities  (as reported)3,804
Total Current Liabilities  (calculated)9,336
+/- 5,532
Long-term Liabilities
Capital Lease Obligations 120
Other Liabilities 2,920
Long-term Liabilities  (as reported)3,740
Long-term Liabilities  (calculated)3,040
+/- 700
Total Stockholder Equity
Common Stock3,442
Total Stockholder Equity (as reported)4,417
Total Stockholder Equity (calculated)3,442
+/- 975
Other
Net Tangible Assets 4,417
Net Working Capital 5,709



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-31
> Total Assets 
2,081
5,369
13,243
26,038
20,145
12,743
5,293
2,044
32,530
25,880
17,278
22,423
11,961
11,96122,42317,27825,88032,5302,0445,29312,74320,14526,03813,2435,3692,081
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
24,998
16,452
19,370
9,513
9,51319,37016,45224,998000000000
       Cash And Cash Equivalents 
1,514
4,917
10,377
13,702
14,454
3,329
2,727
735
30,798
16,774
7,929
11,114
6,163
6,16311,1147,92916,77430,7987352,7273,32914,45413,70210,3774,9171,514
       Short-term Investments 
102
0
386
8,251
1,266
6,975
582
149
164
7,667
7,702
498
130
1304987,7027,6671641495826,9751,2668,2513860102
       Net Receivables 
0
0
0
0
0
0
0
0
0
363
492
2,120
385
3852,120492363000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
2,448
2,448000000000000
       Property Plant Equipment 
356
343
461
1,253
1,301
1,216
1,224
592
546
874
822
640
625
6256408228745465921,2241,2161,3011,253461343356
       Goodwill 
0
0
0
0
1,905
0
0
0
0
0
0
0
0
000000001,9050000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
4
0
6
6040000000000
       Intangible Assets 
0
0
0
0
2,156
0
0
0
0
0
0
0
0
000000002,1560000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
6
6000000000000
> Total Liabilities 
790
7,692
2,144
2,433
4,045
5,901
5,923
2,400
1,630
2,247
2,213
2,803
7,544
7,5442,8032,2132,2471,6302,4005,9235,9014,0452,4332,1447,692790
   > Total Current Liabilities 
748
1,340
1,543
1,865
2,498
2,305
3,318
1,848
1,266
1,938
2,211
2,803
3,804
3,8042,8032,2111,9381,2661,8483,3182,3052,4981,8651,5431,340748
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
3,795
3,795000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
3,795
3,795000000000000
       Accounts payable 
195
395
745
516
1,030
654
1,152
584
754
906
563
620
872
8726205639067545841,1526541,030516745395195
       Other Current Liabilities 
230
762
750
1,102
1,387
1,526
2,117
1,234
512
1,032
1,648
656
874
8746561,6481,0325121,2342,1171,5261,3871,102750762230
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
3,740
3,740000000000000
> Total Stockholder Equity
1,291
0
11,099
23,605
16,100
6,842
0
0
30,900
23,633
15,065
19,620
4,417
4,41719,62015,06523,63330,900006,84216,10023,60511,09901,291
   Common Stock
0
0
6
27
34
32
46
108
1,379
1,609
1,830
3,194
3,442
3,4423,1941,8301,6091,37910846323427600
   Retained Earnings Total Equity0000000000000
   Accumulated Other Comprehensive Income 0000000000000
   Capital Surplus 0000000000000
   Treasury Stock0000000000000
   Other Stockholders Equity 0000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2016-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue9,234
Cost of Revenue-7,439
Gross Profit1,7951,795
 
Operating Income (+$)
Gross Profit1,795
Operating Expense-24,898
Operating Income-15,664-23,103
 
Operating Expense (+$)
Research Development3,156
Selling General Administrative14,303
Selling And Marketing Expenses0
Operating Expense24,89817,459
 
Net Interest Income (+$)
Interest Income10
Interest Expense-0
Other Finance Cost-601
Net Interest Income-591
 
Pretax Income (+$)
Operating Income-15,664
Net Interest Income-591
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-16,267-15,652
EBIT - interestExpense = -12,635
-16,267
-16,233
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-12,635-16,267
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-16,267
Tax Provision--34
Net Income From Continuing Ops-16,233-16,233
Net Income-16,233
Net Income Applicable To Common Shares-16,233
 
Non-recurring Events
Discontinued Operations-3,049
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-12591
 

Technical Analysis of Rosetta Genomics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rosetta Genomics Ltd. The general trend of Rosetta Genomics Ltd is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rosetta Genomics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Rosetta Genomics Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0001 < 0.0001 < 0.0001.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Tweet this
Rosetta Genomics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Rosetta Genomics Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Rosetta Genomics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Rosetta Genomics Ltd. The current macd is 0.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rosetta Genomics Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Rosetta Genomics Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Rosetta Genomics Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Rosetta Genomics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartRosetta Genomics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Rosetta Genomics Ltd. The current adx is 0.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is 0/(-7 +7).

  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Rosetta Genomics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Rosetta Genomics Ltd. The current sar is 0.0001.

Rosetta Genomics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Rosetta Genomics Ltd. The current rsi is 0. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Rosetta Genomics Ltd Daily Relative Strength Index (RSI) ChartRosetta Genomics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Rosetta Genomics Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rosetta Genomics Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Rosetta Genomics Ltd Daily Stochastic Oscillator ChartRosetta Genomics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Rosetta Genomics Ltd. The current cci is -66.66666667.

Rosetta Genomics Ltd Daily Commodity Channel Index (CCI) ChartRosetta Genomics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Rosetta Genomics Ltd. The current cmo is 0.

Rosetta Genomics Ltd Daily Chande Momentum Oscillator (CMO) ChartRosetta Genomics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Rosetta Genomics Ltd. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Rosetta Genomics Ltd Daily Williams %R ChartRosetta Genomics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Rosetta Genomics Ltd.

Rosetta Genomics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Rosetta Genomics Ltd. The current atr is 0.

Rosetta Genomics Ltd Daily Average True Range (ATR) ChartRosetta Genomics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Rosetta Genomics Ltd. The current obv is 387.00.

Rosetta Genomics Ltd Daily On-Balance Volume (OBV) ChartRosetta Genomics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Rosetta Genomics Ltd. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Rosetta Genomics Ltd Daily Money Flow Index (MFI) ChartRosetta Genomics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Rosetta Genomics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal

6.3. Candlestick Patterns

Rosetta Genomics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Rosetta Genomics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Rosetta Genomics Ltd with someone you think should read this too:
  • Are you bullish or bearish on Rosetta Genomics Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rosetta Genomics Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Rosetta Genomics Ltd

I send you an email if I find something interesting about Rosetta Genomics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Rosetta Genomics Ltd.

Receive notifications about Rosetta Genomics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.